Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
Provided By GlobeNewswire
Last update: Jul 30, 2024
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS)
Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders
Read more at globenewswire.com
